Show simple item record

dc.contributor.authorLopez, AL*
dc.contributor.authorDeen, J*
dc.contributor.authorAzman, AS*
dc.contributor.authorLuquero, FJ*
dc.contributor.authorKanungo, S*
dc.contributor.authorDutta, S*
dc.contributor.authorvon Seidlein, L*
dc.contributor.authorSack, DA*
dc.date.accessioned2017-12-20T23:51:51Z
dc.date.available2017-12-20T23:51:51Z
dc.date.issued2017-11-21
dc.date.submitted2017-12-15
dc.identifier.citationImmunogenicity and Protection from a Single Dose of Internationally available killed oral Cholera Vaccine: a systematic review and meta-analysis. 2017 Clin. Infect. Dis.en
dc.identifier.issn1537-6591
dc.identifier.pmid29177437
dc.identifier.doi10.1093/cid/cix1039
dc.identifier.urihttp://hdl.handle.net/10144/619049
dc.description.abstractIn addition to improved water supply and sanitation, the two-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efficacy and effectiveness) conferred by a single OCV dose against cholera. The meta-analysis showed an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, after an OCV first dose. The estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufficient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggests otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.
dc.language.isoenen
dc.publisherOxford University Pressen
dc.rightsArchived with thanks to Oxford University Press and the Infectious Disease Society of America.en
dc.titleImmunogenicity and Protection from a Single Dose of Internationally available killed oral Cholera Vaccine: a systematic review and meta-analysisen
dc.identifier.journalClinical Infectious Diseasesen
refterms.dateFOA2019-03-04T13:40:08Z
html.description.abstractIn addition to improved water supply and sanitation, the two-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efficacy and effectiveness) conferred by a single OCV dose against cholera. The meta-analysis showed an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, after an OCV first dose. The estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufficient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggests otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.


Files in this item

Thumbnail
Name:
2017 Lopez AL Immunogenicity and ...
Size:
838.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record